NIH clinical trial of investigational vaccine for COVID-19 begins

(NIH/National Institute of Allergy and Infectious Diseases) A Phase 1 clinical trial evaluating an investigational vaccine designed to protect against COVID-19 has begun at Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle. The National Institute of Allergy and Infectious Diseases (NIAID), is funding the trial. KPWHRI is part of NIAID's Infectious Diseases Clinical Research Consortium. The open-label trial will enroll 45 healthy adult volunteers ages 18 to 55 years over ...